Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223865 | 0.85 | MEN1 (0.58) | MEN1KMT2AMAPTGAAALOX12 | |
| SCHEMBL5568145 | 0.85 | MEN1 (0.53) | MEN1KMT2AMAPTGAAALOX12 | |
| SCHEMBL20604787 | 0.85 | MEN1 (0.58) | MEN1KMT2AMAPTGAAALOX12 | |
| SCHEMBL1003347 | 0.85 | MEN1 (0.58) | MEN1KMT2AMAPTGAAALOX12 | |
| Hydrochloric Acid SCHEMBL4883396 | 0.82 | MEN1 (0.54) | MEN1KMT2AMAPTGAAALOX12 | |
| SCHEMBL4991415 | 0.79 | MEN1 (0.47) | MEN1KMT2AMAPTGAAALOX12 | |
| SCHEMBL5608428 | 0.77 | MEN1 (0.46) | MEN1KMT2AMAPTGAAALOX12 | |
| SCHEMBL8498553 | 0.77 | GRIN1 (0.62) | MEN1KMT2AMAPTGAAALOX12 | |
| Methyl Alcohol SCHEMBL28176117 | 0.77 | GRIN1 (0.48) | MEN1KMT2AMAPTHTTSLC22A1 | |
| SCHEMBL3382980 | 0.77 | GRIN1 (0.46) | MEN1KMT2AMAPTHTTSLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001848-A1 | ROCK INHIBITORS AND USES THEREOF | ALCON INC (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021262426-A9 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021262426-A2 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210171521-A1 | ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019018185-A1 | ENANTIOMERICALLY PURE ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2550258-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| EP-2550258-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| CN-102333765-A | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2404908-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | Teijin Pharma Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | TEIJIN PHARMA LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2011119345-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171521-A1 | ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION | ADRB3, FPR3, RTN3 | MEN1 2340/4885KMT2A 3130/4885MAPT 3884/4885 |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | XDH, PAH, HPRT1 | MEN1 2690/4885KMT2A 2314/4885MAPT 1383/4885 |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885MAPT 4105/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | MEN1 3448/4885KMT2A 1728/4885MAPT 3614/4885 |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885MAPT 4105/4885 |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | MEN1 1757/4885KMT2A 3318/4885MAPT 3151/4885 |
| US-20260001848-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, PRKG1 | MEN1 652/4885KMT2A 2332/4885MAPT 643/4885 |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ADRB3, FPR3, RTN3 | MEN1 2340/4885KMT2A 3130/4885MAPT 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.